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INTRODUCTION
The standard methodologies for the design
and conduction of randomized controlled
trials (RCTs) are often difficult to be
directly applied when older persons com-
pose the target population (Pahor and
Cesari, 2012). In fact, specific methodolog-
ical adaptations are often required to guar-
antee the feasibility of the trial, ensure the
participants’ adherence/compliance to the
protocol, and allow the unbiased/proper
interpretation of the findings. In this paper,
we present the case of a frequently ignored
issue potentially affecting the interpreta-
tion of results generated by RCTs. In par-
ticular, we describe how the health sta-
tus fluctuations of older persons (espe-
cially in the presence of frailty) may bias
the randomization procedures. Possible
solutions to such phenomenon are also
offered.
CLINICAL TRIALS IN OLDER PERSONS
Randomized controlled trials represent the
gold standard for the assessment of efficacy
and effectiveness of interventions. Given
the socio-demographic trends of our soci-
eties, the conduction of trials in older per-
sons is growingly becoming pivotal. How-
ever, old age often implies special chal-
lenges in the design of intervention studies
from methodological, clinical, and social
viewpoints (Pahor and Cesari, 2012). In
particular, the representativeness of the
study sample (and, consequently, the possi-
ble future generalization of the study find-
ings) is often affected by the complexity of
this population.
The definition of eligibility criteria in
the design of RCTs always represents a cru-
cial and delicate step. The choices done at
this time can drastically change the results
of the study and concur at determining the
success of the project. Such step becomes
even more difficult when the trial is aimed
at exploring age-related conditions. In fact,
the (sub)clinical accumulation of deficits
occurring with aging leads to pathophys-
iological modifications potentially mining
the “purity” of diseases (Cesari et al., 2013).
The age-related reduction of homeosta-
tic mechanisms against entropic forces (or
frailty) (Morley et al., 2013) exposes the
older organism at multiple and interacting
conditions whose clinical manifestations
might often be masked or altered (Stu-
denski, 2009). This issue is at the basis of
the well-known “evidence based medicine”
problem severely affecting the applicability
of clinical recommendations and guide-
lines to elders (Scott and Guyatt, 2010).
On one side, we cannot ignore the need
of extending as much as possible the study
of interventions to the most fastly grow-
ing subgroup of our societies (both in
absolute as well as relative terms). On the
other hand, we also need to acknowledge
a certain inadequacy of traditional stan-
dards adopted in clinical trials for judg-
ing the efficacy of interventions in the
most advanced phases of the aging process
(Pahor and Cesari, 2012).
EVOLUTION OF AGE-RELATED
CONDITIONS
If time plays a major and evident role in
the determination of clinical phenotypes,
ignoring its importance in the design of
the study and the definition of eligibil-
ity criteria may severely affect the con-
duction of the trial and potentially bias
its conclusions. This is particularly true
for evolving clinical processes character-
ized by non-linear trajectories, such as the
age-related disabling cascade commonly
depicted as a sigmoidal decline of physi-
cal function or a self-feeding and acceler-
ating vicious cycle (Ferrucci et al., 2002).
If the development of a clinical condition
does not follow a linear pattern (as fre-
quently happening among older persons)
a single-point or mono-dimensional eval-
uation may not be sufficient to adequately
appreciate the health status of the indi-
vidual. In other words, the history of the
condition of interest imposes to take into
account the often ignored “horse-racing
effect” when designing an ad hoc RCT.
THE HORSE-RACING EFFECT
The horse-racing effect has been origi-
nally advocated to explain observational
studies exploring the increase of clini-
cal parameters (e.g., blood-pressure) with
aging (Anonymous, 1981). It postulates
the existence of a close correlation between
the aging process and the health status
as the speed of the horse is related to its
position in the race. Nevertheless, a super-
ficial observation of results may lead to
arguable conclusions. Thus, for example,
the interpretation of results showing that
blood-pressure increases with advancing
age might meaningfully shift from “the
higher they start, the faster they rise” to
“the faster they rise, the higher they are”
(Peto, 1981). Such contradicting interpre-
tation does not only affect the analysis of
results coming from observational stud-
ies. The same risk can easily endanger the
correct decoding of findings from RCTs.
In Figure 1, a graphical description of
the relevance of the horse-racing effect in
RCTs is provided. Figure 1A depicts the
characteristic and schematic overview of
results from a RCT. At the time 0 visit (V 0),
participants are randomized according to
a major clinical characteristic rendering
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FIGURE 1 | Graphical description of the “horse-racing effect” in randomized clinical trials. V 0 and
V 1 indicate the assessments conducted at the baseline and follow-up visits of the trial, respectively. V −n
represents a hypothetical assessment conducted some time before V 0. x, y, and z describe the
trajectories of the variable of interest for the three randomization groups of the trial. Although the three
groups (x, y, and z ) seem to be correctly randomized and starting at a similar level at the baseline visit
(A), they are indeed characterized by pre-existing differences in their trajectories (B). Such differences
significantly affect the interpretation of trial results.
the intervention groups as much homoge-
neous as possible in relationship with the
study outcome. Let’s say, for example, a
Mini Mental State Examination (MMSE)
score ≥24 to explore the risk of incident
dementia. After two or more interventions
are conducted for a certain period of time,
we can judge the effects of the different trial
arms by comparing the difference of the
key variable of interest between V 1 (end
of the trial visit) and V 0 (baseline visit).
Such approach is legitimate and frequently
adopted, but presents a high risk of biased
results due to: (1) the limited observation
of the phenomenon of interest, and (2) the
fluctuating value of the variable of inter-
est. In fact, the randomization procedure
according to a specific and single criterion
may not adequately take into account what
happened before the observation began in
the three groups. It is like looking at a pic-
ture shot at the photo-finish during a horse
race: we get the idea about the winner, but
our conclusion is justified only because we
are sure that horses indeed began running
together and from the same stating-point at
the gunshot. Translating such concept into
the reality of RCTs, it becomes evident that
the observation period (i.e., trial follow-
up) is infinitesimally shorter compared to
the race already covered before the baseline
visit (i.e., participant’s life-course), espe-
cially if the subject is an older person. In
other words, Figure 1A becomes arguable
and misleading if what happened before
the baseline visit is not adequately consid-
ered. In fact, the positive effect of an inter-
vention (x) compared to the others (y and
z) might be simply be explained by the less
steep decline that participants in that group
were already experiencing before the ran-
domization phase. If the observation could
be left-extended to any previous time-point
V−n (Figure 1B), the interpretation of the
x, y, and z trajectories will lead to com-
pletely different conclusions (i.e., lack of
relevant effects). After all, since between
two points only one line can be drawn, the
identification of a third point (e.g., V−n)
in the appreciation of results will allow
to determine possible knots of flection
and provide a more accurate evaluation of
results.
Just to give an example, a cluster-
randomized trial was conducted to explore
the effectiveness of a specific care
plan in patients with mild-to-moderate
Alzheimer’s disease (Nourhashemi et al.,
2010). The main eligibility criteria of the
trial were the possible or probable diagno-
sis of Alzheimer’s disease, and MMSE score
between 12 and 26. As also mentioned by
the Authors among the study limitations,
the selection of participants (largely rely-
ing on the MMSE results for judging the
cognitive status) might have been biased
the entry criteria, and potentially affected
the homogeneity of the sample.
HOW TO TAKE INTO ACCOUNT THE
HORSE-RACING EFFECT IN CLINICAL
TRIALS
In order to allow the correct interpretation
of RCTs (especially for age-related con-
ditions), the clinical, behavioral, biologi-
cal, and social experiences occurred before
the study start cannot be overlooked. The
definition of the entry criteria based on
a multiple-point observation (for exam-
ple, a test administered twice at the dis-
tance of some time to guarantee the sta-
bility of the condition) might represent
a solid method for limiting the “horse-
racing effect.” As an alternative, it might
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be chosen to combine a double evalua-
tion of potential participants using the
variable of interest (e.g., MMSE score) in
conjunction with a more global measure
of disease severity (e.g., Clinical Dementia
Rating), with this latter somehow serving
as surrogate of exposure time to the risk
condition. It should not even be under-
estimated the role that specific measures
estimating the aging status of the individ-
ual may play in this context. For exam-
ple, the Frailty Index proposed by Rock-
wood and colleagues (measuring the age-
related deficit accumulation of the indi-
vidual) (Rockwood et al., 2005) or the
usual gait speed (intended as an addi-
tional vital sign) (Cesari, 2011) may sup-
port the results of the measured phenom-
enon by providing additional informa-
tion about the global health status of the
participant.
It might be thought that the random-
ization of participants in the different
arms of the clinical trial might be suf-
ficient to take into account the horse-
racing effect. In fact, it is likely that the
random allocation of participants to the
study interventions might also equally dis-
tribute their characteristics and under-
lying conditions, and consequently the
“abnormal” trajectories. This is not com-
pletely true. The randomization proce-
dures may reduce the risk of an unequal
distribution of participants’ characteris-
tics, but cannot be considered foolproof,
especially for those variables that are not
object of specific stratification. Moreover,
the randomization does not act on the
clear and optimal definition of the sam-
ple population, but is simply aimed at
guaranteeing the fair comparison across
groups. Thus, if the horse-racing effect is
not adequately addressed in the eligibil-
ity criteria of the trial participants, the
resulting groups might be similar (thanks
to the randomization), but still poten-
tially include completely different condi-
tions (e.g., MMSE= 25 may indicate a per-
sons with early signs of neurodegenerative
disorder as well as a person with poor
education).
Last but not least, it is important to
raise awareness about the inadequacy of
the standard methodology adopted in tra-
ditional RCTs (targeting adults) when this
is applied to studies recruiting older partic-
ipants (Pahor and Cesari, 2012). The com-
plexity of the older person (especially in
the presence of geriatric conditions) indeed
requires special adaptations capable to tak-
ing into account his/her extreme vulnera-
bility to stressors. In particular, researchers
should understand the necessity of shift-
ing from a disease-oriented approach (typ-
ical of RCTs in adults) to a holistic and
function-oriented one in order to design
informative and robust RCTs in older per-
sons (Studenski, 2009).
CONCLUSION
The “horse-racing effect” described in the
context of observational studies of aging
represents a major source of confounding
in RCTs, too. Researchers should become
more aware about the risks of conducting
one-point and mono-dimensional assess-
ments at the recruitment phase of inter-
vention studies targeting age-related con-
ditions.
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